Annals of Oncology 8:S37-S42, 1997
© 1997 European Society for Medical Oncology
Use of an anti-ALK antibody in the characterization of anaplastic large-cell lymphoma of childhood
1 State University of New York, Health Science Center Syracuse, NY, USA
2 Pediatric Oncology Group Statistical Office and the University of Florida Gainesville, FL, USA
3 St. Jude Children's Research Hospital Memphis, TN, USA
4 Children's Memorial Hospital, Northwestern University Chicago, IL, USA
5 Stanford University Medical Center Palo Alto, CA, USA
6 Brooke Army Medical Center Ft Sam Houston, TX, USA
7 Medical University of South Cnrolina Charleston, SC, USA
8 University of Massachusetts Medical Center Worcester, MA, USA
9 Medical College of Ohio, Toledo, OH, and the Pediatric Oncology Group Chicago, IL, USA
1Correspondence to: Robert E. Hutchison, MD SUNY-HSC at Syracuse Department of Clinical Pathology 750 E. Adams St. Syracuse, NY 13210 USA
Background Anaplastic lymphoma kinase (ALK) is a tyrosine kinase inappropriately expressed in lymphoid tissue involved by CD30+ anaplastic large-cell lymphoma (ALCL) with the translocation t(2;5)(p23;q35), which juxtaposes the nucleophosmin gene (NPM) with that encoding ALK, resulting in a hybrid (NPM-ALK) message.
Patients and methods A polyclonal antibody against residues of the kinase portion of NPM-ALK (designated anti-ALK 11) was tested for clinical utility in paraffin sections of 44 cases of pediatric large-cell lymphoma (LCL) and 17 additional lymphoma cases, by streptavidin-biotin-alkaline phosphatase method.
Results Nineteen of 20 CD30+ cases (the majority exhibiting anaplastic morphology) labeled with anti-ALK 11, and 5/28 CD30– cases were also ALK+ (3 T cells, 1 null cell, and 1 B cell). Sixteen of 17 B-cell pediatric LCLs were negative, as were 6/6 cases of Hodgkin's disease and 7/7 cases of adult B-cell lymphoma. In pediatric LCLs with adequate follow-up (24/44 ALK+), there was no significant association between ALK expression and two-year event-free survival, similar to the finding reported previously for CD30 expression in these cases.
Conclusions We conclude that the majority of pediatric CD30+ ALCLs show ALK overexpression, consistent with the presence of the t(2;5)-encoded NPM-ALK fusion, but that the clinical significance of this entity remains unproven.
adolescence, ALK antigen, anaplasia, anaplastic large-cell lymphoma, CD30 antigen, child, diagnosis, Ki-1 large-cell lymphoma, non-Hodgkin's lymphoma
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Montalban, A. Santon, C. Redondo, M. Garcia-Cosio, D. Boixeda, E. Vazquez-Sequeiros, F. Norman, C. M. de Argila, I. Alvarez, V. Abraira, et al. Long-term persistence of molecular disease after histological remission in low-grade gastric MALT lymphoma treated with H. pylori eradication. Lack of association with translocation t(11;18): a 10-year updated follow-up of a prospective study Ann. Onc., September 1, 2005; 16(9): 1539 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Montalban, A Santon, D Boixeda, and C Bellas Regression of gastric high grade mucosa associated lymphoid tissue (MALT) lymphoma after Helicobacter pylori eradication Gut, October 1, 2001; 49(4): 584 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Suzuki, Y. Kagami, K. Takeuchi, M. Kami, M. Okamoto, R. Ichinohasama, N. Mori, M. Kojima, T. Yoshino, H. Yamabe, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype Blood, November 1, 2000; 96(9): 2993 - 3000. [Abstract] [Full Text] [PDF]
|
|